The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Ibrutnib in Older Patients With Mantle Cell Lymphoma

Brad S. Kahl, MD
Published Online:3:57 PM, Fri August 3, 2018

Brad S. Kahl, MD, professor in the department of medicine at Washington School of Medicine at Siteman Cancer Center, discusses the use of ibrutinib (Imbruvica) in older patients with mantle cell lymphoma. This agent is currently being investigated in the frontline setting for patients not eligible for stem cell transplant.

SHINE is a larger trial that is fully enrolled, but the readout is not available yet. Patients in this trial were randomized to receive either bendamustine or rituximab (Rituxan), or a combination of bendamustine/rituximab plus ibrutinib. Ibrutinib was also continued as a post-remission therapy, according to Kahl.

Kahl says that ibrutinib has the potential to change the current standard of care for frontline treatment of older patients with mantle cell lymphoma. This agent has previously been approved for relapsed disease and has been used a lot in that setting for mantle cell lymphoma.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.